Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Mesoblast Limited (MESO) Price & Performance

Airbnb, Inc.
Mesoblast Limited

Price performance

Price movement over the last 24 hours

Key statistics

Airbnb, Inc. vs Mesoblast Limited — how do they compare? Airbnb, Inc. trades at $143 (market cap $88.31B), while Mesoblast Limited trades at $13.8 (market cap $1.82B). The key difference: Airbnb, Inc. is far larger — about 48.5× Mesoblast Limited's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

ABNBMESO
Market Cap
$88.31B$1.82B
Sector
Consumer CyclicalTechnology
52-Week High
$148.93$20.96
52-Week Low
$111.54$10.45
Enterprise Value
$78.84B$1.82B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.

The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.

Mesoblast Limited

MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).

Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO